Log In
Print
BCIQ
Print
Print this Print this
 

Subcutaneous MOR103

  Manage Alerts
Collapse Summary General Information
Company MorphoSys AG
DescriptionSubcutaneous formulation of a human HuCal antibody against GM-CSF
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard Indication Inflammation (unspecified)
Indication DetailsTreat chronic inflammatory diseases
Regulatory Designation

Partner

GlaxoSmithKline plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today